×
About 12,078 results

OncLive® Honors 14 Cancer Care Pioneers
https://www.onclive.com/view/onclive-honors-14-cancer-care-pioneers

Oct 15th, 2021 - OncLive® is honored to announce the 2021 Giants of the Cancer Care® inductees. The 14 winners are innovators of change whose invaluable contributions to the field have changed the trajectory of care across tumor types and improved the quality of life for countless patients. Breast Cancer Nancy E. Davidson, MD, Fred Hutchinson Cancer Research Center/ University of Washington School of Medici...

Find the Job That’s Right for You
https://www.onclive.com/view/find-the-job-that-s-right-for-you

Oct 11th, 2021 - The American Society of Clinical Oncology (ASCO) projects significant shortages of practicing oncologists compared with patients with new cancer diagnoses and existing cancer by 2025.1 For an oncologist entering the workforce, this is valuable news. The job search for physicians in the COVID-19 and post–COVID-19 era will undoubtedly be different from any years before 2020. Nonetheless, fellows ...

DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
https://www.onclive.com/view/denunzio-describes-the-advantages-of-proton-beam-therapy-in-oncology

Oct 9th, 2021 - Welcome to OncLive On Air®! I’m your host today, Caroline Seymour. OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In to...

Overcoming Imposter Syndrome as a New Fellow
https://www.onclive.com/view/overcoming-imposter-syndrome-as-a-new-fellow

Oct 7th, 2021 - Welcome to fellowship! You have mastered the art of internal medicine, served as the senior resident for a medicine team, and perhaps even served as a chief medical resident. Now you are a fellowship frosh, and are suddenly being called in the middle of the night to help a patient with hemophilia suffering with a complex bleed. You think, “Am I in over my head? Do I deserve to be here? Am I qua...

Navigating Immune-Related Adverse Effects in Oncology
https://www.onclive.com/view/navigating-immune-related-adverse-effects-in-oncology

Oct 6th, 2021 - The advent of PD-1/PD-L1 and CTLA-4 inhibitors has transformed the treatment of patients with a number of malignancies. However, due to their mechanism of action, patients often develop off-target immune-related adverse effects (irAEs) as a result of their treatment. In a presentation during the 4th Annual School of Nursing Oncology virtual meeting hosted by Physicians’ Education Resource®, LL...

Yale Cancer Center Researchers Awarded $2.8 Million Cancer Systems Immunology Grant
https://www.onclive.com/view/yale-cancer-center-researchers-awarded-usd2-8-million-cancer-systems-immunology-grant

Oct 6th, 2021 - Yale Cancer Center (YCC) researchers were awarded a $2.8 million grant from the National Cancer Institute to evaluate and model cytokine signaling related to immunotherapy for cancer. Cytokines are powerful hormone-like molecules of the immune system that are utilized by a variety of different cell types within tumors to communicate with one another and to send signals to sites outside of the t...

Dr. Burris on the Potential for Novel Checkpoint Inhibitor Combinations in Oncology
https://www.onclive.com/view/dr-burris-on-the-potential-for-novel-checkpoint-inhibitor-combinations-in-oncology

Oct 6th, 2021 - Howard A. Skip Burris, III, MD, FASCO, FACP, chief medical officer and president of Clinical Operations at Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the potential of novel combination strategies with checkpoint inhibitors in oncology. Ongoing trials are evaluating PD-L1 inhibitors in combination with novel therapies, such as TIGIT- and L...

Dr. Palmer on Complications of Acute Graft-Versus-Host Disease
https://www.onclive.com/view/dr-palmer-on-complications-of-acute-graft-versus-host-disease

Oct 6th, 2021 - Jeanne M. Palmer, MD, a hematologist and oncologist in the Department of Hematology and Bone Marrow Transplant Program at Mayo Clinic, discusses common complications associated with acute graft-versus-host disease (aGVHD). Typically, aGVHD involves 3 major organ systems: the skin, gastrointestinal (GI) tract, and liver, says Palmer. Skin involvement can range from a faint red rash to a bl...

Dr. Saba on Scheduling Challenges With Cisplatin in Head and Neck Cancer
https://www.onclive.com/view/dr-saba-on-scheduling-challenges-with-cisplatin-in-head-and-neck-cancer

Oct 6th, 2021 - Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses ​scheduling challenges with cisplatin in head and neck cancer. The head and neck cancer paradigm has been limited in terms of systemic th...

Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer
https://www.onclive.com/view/herzog-and-moore-mull-over-the-role-of-maintenance-parp-inhibition-in-ovarian-cancer

Oct 6th, 2021 - Welcome to a very special edition of OncLive® On Air! I’m your host today, Caroline Seymour. OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important re...

Level 1 Evidence Needed to Drive Optimal Sequencing Strategies in Endometrial Cancer
https://www.onclive.com/view/level-1-evidence-needed-to-drive-optimal-sequencing-strategies-in-endometrial-cancer

Oct 6th, 2021 - Research efforts regarding optimal sequencing in endometrial cancer are needed as the armamentarium continues to expand, explained Brian M. Slomovitz, MD. "We haven't focused on the role of sequencing in endometrial cancer much at all," explained Slomovitz. "In ovarian cancer, we are beginning to learn the optimal order of treatment. However, there are more treatment modalities available in en...

GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer
https://www.onclive.com/view/gu-experts-review-treatment-options-remaining-challenges-and-future-research-in-penile-cancer

Oct 6th, 2021 - Welcome to a very special edition of OncLive® On Air. I’m your host today, Gina Columbus. OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice from new technology to treatment advances to important regula...

FDA Approval Insights: Avelumab in Metastatic Urothelial Carcinoma
https://www.onclive.com/view/fda-approval-insights-avelumab-in-metastatic-urothelial-carcinoma

Oct 6th, 2021 - Welcome to a very special edition of OncLive® On Air! I’m your host today, Caroline Seymour. OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important re...

Dr. Chang on the Impact of COVID-19 on the Surgical Management of GU Cancers
https://www.onclive.com/view/dr-chang-on-the-impact-of-covid-19-on-the-surgical-management-of-gu-cancers

Oct 6th, 2021 - Steven Lee Chang, MD, assistant professor of surgery, Harvard Medical School, associate surgeon, Brigham and Women’s Hospital and Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center, discusses the impact of the coronavirus disease 2019 (COVID-19) on the surgical management of patients with genitourinary (GU) cancers. Many patients with GU cancers do not require immediate surgical ...

Axi-Cel Retreatment Demonstrates Clinical Efficacy in Large B-Cell Lymphoma
https://www.onclive.com/view/axi-cel-retreatment-demonstrates-clinical-efficacy-in-large-b-cell-lymphoma

Oct 6th, 2021 - Findings from an exploratory analysis of the phase 1/2 ZUMA-1 trial demonstrated clinical efficacy in patients with relapsed/refractory large B-cell lymphoma (LBCL) who were retreated with the CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta). The results showed that patients who achieved a CR with the first infusion of axi-cel had a higher likelihood of attaining a CR during re...

Gutierrez Provides Insight on Bridging Gaps in Cancer Care
https://www.onclive.com/view/gutierrez-provides-insight-on-bridging-gaps-in-cancer-care-among-hispanic-patients

Oct 6th, 2021 - Welcome to a very special edition of OncLive On Air™! I’m your host today, Caroline Seymour. OncLive On Air™ is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important re...

Precision Medicine Presents a Disconnect in Oncology Practice
https://www.onclive.com/view/precision-medicine-presents-a-disconnect-in-oncology-practice

Oct 6th, 2021 - The precision medicine revolution has become a major component of cancer treatment. Multiple FDA approvals and an increasing number of clinical trials examining molecular target–based therapeutics, including second- or even third-generation drugs against a well-defined target,1 present an ever-widening array of drugs for routine cancer care based on the discovery of specific molecular targets w...

Patient Advocacy and Education Are Essential for Optimal Cancer Care
https://www.onclive.com/view/patient-advocacy-and-education-are-essential-for-optimal-cancer-care

Oct 6th, 2021 - Encouraging patient advocacy and education are key to overcoming some of the challenges that come with a cancer diagnosis, said Caroline Farrington, PhD, who stressed the importance for providers to help patients not only process their diagnosis, but also answer questions around treatment and adverse effect (AEs) management. It's a very overwhelming and scary experience for patients and it's v...

Roswell Park Cancer Institute: A History of Initiative and Innovation
https://www.onclive.com/view/roswell-park-cancer-institute-a-history-of-initiative-and-innovation

Oct 6th, 2021 - Founded in 1898 by Dr Roswell Park, Roswell Park Cancer Institute (RPCI) is the oldest dedicated comprehensive cancer center in the country. In 1974, the Buffalo, New York, facility was 1 of the first 3 institutions to be National Cancer Institute (NCI)-designated as a comprehensive cancer center. Roswell Park [Cancer Institute] has been ahead of its time from the very start, said president a...

Unprecedented Changes in Oncology: Toward a New Dawn
https://www.onclive.com/view/unprecedented-changes-in-oncology-toward-a-new-dawn

Oct 6th, 2021 - Andre Goy, MD, MS Editor-in-Chief of Oncology & Biotech News Chairman and Director Chief of Lymphoma Director, Clinical and Translational Cancer Research John Theurer Cancer Center at Hackensack University Medical Center Are you making progress? is one of the questions you are most frequently being asked as an oncologist—even in social settings. It is obviously beyond th...